CNVN 202

Drug Profile

CNVN 202

Alternative Names: DOTAP-Chol-fus1; DOTAP-Cholesterol-Fus1 liposome complex; FUS1 cancer gene therapy; INGN-401; Oncoprex

Latest Information Update: 05 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer Genprex
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action FUS1 tumour suppressor protein stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Non-small cell lung cancer

Most Recent Events

  • 27 Sep 2018 Genprex signs agreement with Aldevron to supply TUSC2 plasmid for CNVN 202 development
  • 28 Aug 2018 Genprex amends (updates) its agreement with University of Texas M.D Anderson Cancer Center pertaining the use of TUSC2 platform
  • 02 Aug 2018 Genprex amends (updates) its clinical trial agreement with University of Texas M. D. Anderson Cancer Center concerning a phase I/II trial in Non-small cell lung cancer (Combination therapy)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top